News — VERIMMUNE

PIONEERING ANTI-TUMOR IMMUNE REDIRECTION

VerImmune Completes $4.5 Million First Closing of Pre-Series A Financing, Strengthens Board with Two Accomplished Biotechnology Executives

VerImmune Completes $4.5 Million First Closing of Pre-Series A Financing, Strengthens Board with Two Accomplished Biotechnology Executives

joshua wangSeptember 23, 2024

VerImmune Inc announces the continued growth of its patent portfolio for Virus-inspired Particle (ViP) based Cancer treatment

VerImmune Inc announces the continued growth of its patent portfolio for Virus-inspired Particle (ViP) based Cancer treatment

joshua wangJanuary 25, 2024

VerImmune and A*STAR Sign Research Collaboration Agreement

VerImmune and A*STAR Sign Research Collaboration Agreement

joshua wangJanuary 11, 2024

VerImmune Announces Over $3M Additional Funding

joshua wangSeptember 21, 2023

VerImmune Awarded Amgen X NSG BioLabs Golden Ticket award

VerImmune Awarded Amgen X NSG BioLabs Golden Ticket award

joshua wangJuly 28, 2023

VerImmune Announces Positive Pre-IND Meeting with FDA

joshua wangMay 23, 2023

VerImmune Awarded $500K SBIR Phase IIB Follow-on Funding from the National Science Foundation

VerImmune Awarded $500K SBIR Phase IIB Follow-on Funding from the National Science Foundation

joshua wangApril 29, 2023

VerImmune Inc Announces Upcoming Oral and Poster Presentations at the 35th IPV and AACR Annual meeting 2023

VerImmune Inc Announces Upcoming Oral and Poster Presentations at the 35th IPV and AACR Annual meeting 2023

joshua wangMarch 17, 2023

VerImmune, Inc. Announces Issuance of Second U.S Patent Protecting Proprietary Technology Platform

VerImmune, Inc. Announces Issuance of Second U.S Patent Protecting Proprietary Technology Platform

joshua wangFebruary 17, 2023

VerImmune accepted into the Nanotechnology Characterization Laboratory at Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute

VerImmune accepted into the Nanotechnology Characterization Laboratory at Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute

joshua wangAugust 12, 2022

VerImmune Inc Announces Closing of Seed Financing to Further Develop Novel Virus-inspired Particle Immunotherapies

joshua wangJuly 27, 2022

VerImmune's scientific advisors publishes independent supportive data on Anti-tumor Immune Redirection (AIR) in PNAS

VerImmune's scientific advisors publishes independent supportive data on Anti-tumor Immune Redirection (AIR) in PNAS

joshua wangJuly 14, 2022

VerImmune and Fosun Pharma enter into an Exclusive License and Option Agreement for VerImmune’s Virus-inspired Particle (ViP) platform as Novel Immunotherapies in China

VerImmune and Fosun Pharma enter into an Exclusive License and Option Agreement for VerImmune’s Virus-inspired Particle (ViP) platform as Novel Immunotherapies in China

joshua wangMay 20, 2022

VerImmune, Inc. Announces Issuance of U.S Patent Protecting Proprietary Technology Platform

VerImmune, Inc. Announces Issuance of U.S Patent Protecting Proprietary Technology Platform

joshua wangApril 5, 2022

VerImmune Announces Research Collaboration with Janssen to Leverage its Unique Immuno-oncology therapeutic Platform

joshua wangFebruary 9, 2022

VerImmune Expands Scientific Advisory Board with Appointment of Prof. Narayanan Gopalakrishna Iyer MBBS (Hons), PhD , FRCS (Gen), FAMS

VerImmune Expands Scientific Advisory Board with Appointment of Prof. Narayanan Gopalakrishna Iyer MBBS (Hons), PhD , FRCS (Gen), FAMS

joshua wangJune 1, 2021

VerImmune Receives SBIR Phase II Award from the National Science Foundation

VerImmune Receives SBIR Phase II Award from the National Science Foundation

VerImmune Receives SBIR Phase II Award from the National Science Foundation

joshua wangSeptember 2, 2020

VerImmune Announces New Board, Advisors and Officers

Michaela FlatleyJanuary 13, 2020

VerImmune to Present at Biotech Showcase™ 2020 in San Francisco

VerImmune to Present at Biotech Showcase™ 2020 in San Francisco

Michaela FlatleyJanuary 10, 2020